Stockscreener 앱 받기
0.00
2.94%
-0.102
Neximmune Inc 주식(NEXI)의 최신 뉴스
Menin Inhibitors Market Forecasts Signal Strong Uptake of Menin Inhibitors in Hematologic Oncology Across the 7MM During the Forecast Period (2020-2034) | DelveInsight - PR Newswire UK
Acute Myeloid Leukemia Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight - openPR.com
Analyzing Theratechnologies (NASDAQ:THTX) and NexImmune (NASDAQ:NEXI) - Defense World
TIBSOVO's Continued Success Solidifies Its Position as a Leader in IDH1 Mutant Space | DelveInsight - The Malaysian Reserve
Vanotech Appoints Matthew Schiller to Lead Business Development - citybiz
Vanotech appoints Matthew Schiller to Lead Business Development - EFECOMUNICA
Reviewing NexImmune (NASDAQ:NEXI) & Benitec Biopharma (NASDAQ:BNTC) - Defense World
NexImmune (NASDAQ:NEXI) Stock Price Down 15.2% – Should You Sell? - Defense World
North American Morning Briefing : Tesla, Chip -2- -January 03, 2025 at 06:08 am EST - Marketscreener.com
Immunomodulators Market Size to Worth Around US$ 1,237.66 Bn by 2033 - BioSpace
NexImmune moves forward with wind-down process - The Business Journals
NexImmune Dissolution Progresses with New Sole President - TipRanks
NexImmune shareholders approve company dissolution - Investing.com
What Are the Rules Behind the Delisting of a Stock? - Investopedia
NEXI Stock Alert: NexImmune Delists From Nasdaq - InvestorPlace
What Is Going on With NexImmune (NEXI) Stock Today? - InvestorPlace
Why HighPeak Energy Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session - Markets Insider
NexImmune Announces Closing of $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Yahoo Finance
Why 4D Molecular Therapeutics Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket - markets.businessinsider.com
NexImmune Ends Stock Sale Agreement, Raises $5.1 Million - TipRanks
Neximmune terminates equity sales agreement and ATM program - TipRanks
NexImmune Announces $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Stock Titan
NexImmune (NEXI) Stock Rockets 80% Ahead of Potential Liquidation - TradingView
Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session - Benzinga
NexImmune's future in limbo as Gaithersburg biotech extends liquidation vote - The Business Journals
NEXI Stock Halted: What’s Going on With NexImmune Shares Today? - InvestorPlace
Gaithersburg biotech prepares to shut down, lay off ‘substantially all’ employees - The Business Journals
Gaithersburg’s NexImmune prepares to shut down, lay off ‘substantially all’ employees - The Business Journals
Why Neximmune (NEXI) Stock Is Getting Hammered - TradingView
Rockville cancer therapy firm Sensei Biotherapeutics faces delisting threat from Nasdaq - The Business Journals
D.C.'s Vanda Pharmaceuticals to ask Supreme Court to review patent infringement lawsuit - The Business Journals
NexImmune (NASDAQ: NEXI) to jump 2,500% todaya purely technical move - Dhaka Tribune
NexImmune to lay off over half of its employees - Pharmaceutical Technology
NexImmune Announces Workforce Reduction to Enable Continued AIMTM Nanoparticle Platform Development Strategy - Stock Titan
An analysis of a first-in-human study of NEXI-001 donor-derived antigen-specific CD8+ T-cell treatment of relapsed AML after allogeneic hematopoietic cell transplantation (HCT). - ASCO Publications
Sirnaomics spinout RNAImmune launching clinical trial for Covid-19 vaccine booster - The Business Journals
Gaithersburg biotech Salubris Biotherapeutics clinches $35M investment for R&D - The Business Journals
Silver Spring's Aziyo Biologics laying off 12% of workforce - The Business Journals
Why NexImmune (NEXI) Shares Are Trading Higher TodayNexImmune (OTC:NEXI) - Benzinga
Barer Sol J Increases Position in NexImmune (NEXI) - Nasdaq
Tech Transfer Roundup: Tiba And CEPI Strategize Together On ‘Disease X’ - insights.citeline.com
AIM™ platform: A new immunotherapy approach for viral diseases - Frontiers
Life Sciences Firm Closing 2 Maryland Facilities, Laying Off Workers - Bisnow
Analyst Downgrades NexImmune After Going Back To Preclinical Stage - Yahoo Finance
Selexis and NexImmune Sign Service Agreement to Advance Multiple Immunotherapies Targeting Rare Cancers and Autoimmune Disorders - Business Wire
Refractory Multiple Myeloma Pipeline Analysis of 80+ therapies: Key Pharma Players Set to Develop Novel Therapies - GlobeNewswire
Global Human Papillomavirus Associated Cancer Pipeline - GlobeNewswire
Zephyr AI Announces Additions to the Board of Directors - Business Wire
Pharma50: 50 Leading Cell and Gene Therapy Companies - drugdiscoverytrends.com
What Makes NexImmune, Inc. (NEXI) a New Buy Stock - Nasdaq
NexImmune Appoints Dr. Leena Gandhi To Board - citybiz
NexImmune Promotes Mathias Oelke, Ph.D., To Chief Scientific Officer - citybiz
63 Biggest Movers From Yesterday - Benzinga
D.C. Council member ends effort to reinstate proof of vaccination requirement to enter businesses - The Business Journals
NexImmune Appoints Kristi Jones as CEO - citybiz
Launch of Generium’s Omalizumab Biosimilar for Atopic Bronchial Asthma Marks Selexis’ Ninth Commercial Product - Business Wire
It's been a tough year so far on Wall Street. These D.C.-area companies have suffered the biggest hits. - The Business Journals
Selexis and Inotrem Enter Service Agreement to Advance Inotrem’s Chronic Inflammatory Disease Program - Business Wire
MedStar Georgetown University Hospital lands $50M donation - The Business Journals
Johns Hopkins Tech Ventures startups saw $1B in investment in fiscal 2021 - The Business Journals
Selexis Appoints Roland Hoffmann- Hecht, PhD, as Chief Business Officer - Business Wire
Great Place to Work® Designates Selexis as One of the Best Workplaces™ Switzerland for Fourth Straight Year - Business Wire
Here's What NexImmune, Inc.'s (NASDAQ:NEXI) Shareholder Ownership Structure Looks Like - Yahoo Finance
In Their Own Words With Private-Equity Investors in Healthcare - WSJ
Selexis and Tallac Therapeutics Collaborate to Advance Tallac’s Pipeline of Novel Immunotherapies in Oncology - Business Wire
Md. biotech plans aggressive hiring, growth with IPO proceeds in hand - The Business Journals
Biotech Startups Gain Leverage as IPOs, SPACs Beckon - The Wall Street Journal
Finance Watch: SPAC Spree To Continue ‘For Foreseeable Future’ - insights.citeline.com
0.29%
자본화:
|
볼륨(24시간):